BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 20881957)

  • 1. Therapeutic potential of oncolytic measles virus: promises and challenges.
    Galanis E
    Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Measles virus: a future therapeutic agent in oncology?].
    Touchefeu Y; Schick U; Harrington KJ
    Med Sci (Paris); 2012 Apr; 28(4):388-94. PubMed ID: 22549866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic vaccinia virus: from bedside to benchtop and back.
    Thorne SH
    Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
    Allen C; Vongpunsawad S; Nakamura T; James CD; Schroeder M; Cattaneo R; Giannini C; Krempski J; Peng KW; Goble JM; Uhm JH; Russell SJ; Galanis E
    Cancer Res; 2006 Dec; 66(24):11840-50. PubMed ID: 17178881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
    Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
    Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally oncolytic viruses.
    Roberts MS; Lorence RM; Groene WS; Bamat MK
    Curr Opin Mol Ther; 2006 Aug; 8(4):314-21. PubMed ID: 16955694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
    Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
    Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
    Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
    Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus combinations and chemotherapy for the treatment of human cancers.
    Kumar S; Gao L; Yeagy B; Reid T
    Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
    Fournier P; Bian H; Szeberényi J; Schirrmacher V
    Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
    Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
    Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measles as a potential oncolytic virus.
    Fielding AK
    Rev Med Virol; 2005; 15(2):135-42. PubMed ID: 15546127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling of cancer virotherapy with recombinant measles viruses.
    Bajzer Z; Carr T; Josić K; Russell SJ; Dingli D
    J Theor Biol; 2008 May; 252(1):109-22. PubMed ID: 18316099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic measles virus strains in the treatment of gliomas.
    Allen C; Paraskevakou G; Liu C; Iankov ID; Msaouel P; Zollman P; Myers R; Peng KW; Russell SJ; Galanis E
    Expert Opin Biol Ther; 2008 Feb; 8(2):213-20. PubMed ID: 18194077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulation in Oncolytic Measles Virotherapy.
    Dietz L; Engeland CE
    Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential and clinical translation of oncolytic measles viruses.
    Robinson S; Galanis E
    Expert Opin Biol Ther; 2017 Mar; 17(3):353-363. PubMed ID: 28129716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuated, oncolytic, but not wild-type measles virus infection has pleiotropic effects on human neutrophil function.
    Zhang Y; Patel B; Dey A; Ghorani E; Rai L; Elham M; Castleton AZ; Fielding AK
    J Immunol; 2012 Feb; 188(3):1002-10. PubMed ID: 22180616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of attenuated paramyxoviruses for cancer therapy.
    Lech PJ; Russell SJ
    Expert Rev Vaccines; 2010 Nov; 9(11):1275-302. PubMed ID: 21087107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. United virus: the oncolytic tag-team against cancer!
    Le Boeuf F; Bell JC
    Cytokine Growth Factor Rev; 2010; 21(2-3):205-11. PubMed ID: 20227326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.